## **IRT's Peptide Mimetic Technology**

Irimajiri Therapeutics, Inc. (IRT)

## Alkaloid Compound Library System (ACLS)

1. IRT Technology to inhibit PPI by using peptide mimicking compound which has cage-shape template and rigid side chain direction.



IRT compound inhibits PPI efficiently by covering the key interaction site, which is usually small interface. Side chains

## 2. Establishment of IRT peptide-mimetic technology -Research into rabies virus inhibitors-

Oita University's microbiology department has extensively studied the rabies virus.

2a cells

were inhibited.

Inclusion body: This structure is essential for rabies virus growth



Deletion of 19 amino acids from the N-protein Cterminal domain prevents inclusion body formation Oita University result



Alanine mutant ir 438 (F → A). The formation of inclusion bodies





The C-terminal IDP domain (19 amino acids) formed a helical structure in the inclusion body (green), of which three amino acids were shown to be essential by alanine scan

3. ACLS consists of compound that are build on 6 different cage shape templates with 3 side chain arms which mimic a part of protein(s).



Highly likely one of the compound will interact with target protein

- 10 amino acids which are frequently seen in PPI have been selected.
- Combination of 3 amino acids and 6 different core scaffold total 6000 compounds



## 4. Activity data analysis in ALS targets (SOD1 – Derlin-1)





- 2000 compounds evaluated includes 4 different cage scaffold (CS-1~4)
- > Compound with different scaffold and same side chain showed
- opposite results (CS-1:positive, CS-2, 3, 4: negative)
- > Difference in the angle of the side chains between 4 core scaffold is only 5-10 dearees

5. 3D analysis Activity General Compound Library Image of the data based on compounds that are generally ACLS used as compound libraries. Most of compounds holding similar structure Compounds with similar structure usually show similar with hit compound showed low efficacy. efficacy.

- **6. IRT propose:** > ACLS can be supplied without structure information.
  - > When any active compounds are found, IRT can supplied the derivatives of the active compounds.
  - > Partner and IRT can jointly file several selective patents.
  - > Partner can solely hold the right of their clinical compound(s).